EMFLAZA® (deflazacort) is a corticosteroid that demonstrates anti-inflammatory and immunosuppressant effects.

Status

EMFLAZA® is indicated for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older (download EMFLAZA® label & prescribing information).

For additional resources regarding eligibility and access, view PPMD’s Insurance Access & Coverage Roadmap.

Sponsor

This program is sponsored by PTC Therapeutics.

Media Library